Last reviewed · How we verify
albuterol (Ventolin)
Albuterol is a beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles and increasing air flow to the lungs.
Albuterol is a beta-2 adrenergic receptor agonist that works by relaxing bronchial muscles and increasing air flow to the lungs. Used for Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD), Prevention of bronchospasm during exercise.
At a glance
| Generic name | albuterol (Ventolin) |
|---|---|
| Also known as | Ventolin |
| Sponsor | AstraZeneca |
| Drug class | beta-2 adrenergic receptor agonist |
| Target | beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 3 |
Mechanism of action
This is achieved by binding to beta-2 adrenergic receptors in the bronchial smooth muscle, leading to an increase in cyclic AMP and subsequent relaxation of the muscle cells. This results in bronchodilation and improved lung function.
Approved indications
- Maintenance and relief of bronchospasm in asthma and chronic obstructive pulmonary disease (COPD)
- Prevention of bronchospasm during exercise
Common side effects
- Tremors
- Nervousness
- Headache
- Dizziness
- Palpitations
Key clinical trials
- A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations (PHASE3)
- High Flow Nasal Cannula Rates in Pediatric Asthma (NA)
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma (PHASE2)
- Nebulized or Inhaled Albuterol for Lymphangioleiomyomatosis (PHASE1, PHASE2)
- A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma (PHASE3)
- A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma (PHASE4)
- A Study to Investigate Efficacy and Safety of PT027 Compared With PT007 in Symptomatic Chinese Adults With Asthma (PHASE3)
- GRANITE: Airsupra Effectiveness in the Real World
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |